On 13 November, the United States Federal Trade Commission (FTC) went to court to stop a $3.5bn vet supply merger between two of the country’s largest distributors, and thirteen state attorneys general joined the case. Veterinary distribution consolidation is not an abstract topic here. The regulators argue that fewer distributors between manufacturers and clinics means clinics pay more for what they buy, and that the cost reaches the pet owner. The companies say the regulators have drawn the market too narrowly. However, the court has not decided anything yet.
What was filed
| Detail | What was filed |
|---|---|
| Date | 13 November 2026 |
| The deal | Covetrus’s proposed $3.5 billion acquisition of MWI, the veterinary distribution business of Cencora (also known as MWI Animal Health) |
| Covetrus owners | Private equity firms Clayton, Dubilier & Rice and TPG |
| Seller | Cencora, which agreed the sale in February 2026 and would keep a minority stake in the combined business |
| Court | US District Court, Southern District of New York |
| States joining | Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas |
| Commission vote | 2–0 to authorise staff to seek a permanent injunction |
| Markets alleged | Distribution to veterinary clinics, and distribution to large corporate accounts |
The FTC alleges that the combined firm would drive up costs for clinics, lower service quality and raise prices for pet owners. Daniel Guarnera, Director of the FTC’s Bureau of Competition, said the two companies “are engaged in fierce head-to-head competition,” and that “Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers.”
However, these are only allegations in a complaint, not findings. Therefore, the defendants intend to contest the case.
Why distribution matters to clinics
A veterinary clinic usually does not buy most of its stock straight from the manufacturer. Vaccines, injectables, consumables, diagnostics and dispensary items often arrive through a distributor. That distributor holds inventory, extends credit, runs the ordering system and sets terms.
According to the FTC, the two merging firms are the largest suppliers in both alleged markets, and they are each other’s closest competitor. Earlier reporting described the proposed deal as combining the two largest national distributors, with a third large national player and some regional firms also active. The FTC’s own release does not state how many national distributors there are, and it gives no market share figures. Meanwhile, unofficial share estimates have circulated, but none comes from a regulator. As a result, this article does not repeat them.
Furthermore, the case did not come from nowhere. In August, reporting said the FTC had sent information requests to veterinary customers and industry competitors while it examined the deal. The lawsuit is the end of that review.
The mechanism the complaint describes
The most instructive part of the filing is how the FTC says these two firms actually compete. It names two features.
- Rebates. The FTC alleges that Covetrus responded to its rival’s aggressive pricing by cutting prices and offering rebates through a loyalty programme. In distribution, the real money is often in rebates, volume tiers and payment terms, not list prices.
- A price-comparison platform. The FTC says an online platform lets veterinarians compare prices and use one distributor’s offer to negotiate with the other, which intensified head-to-head competition.

The FTC describes years of an “all-out price war” and alleges that smaller rivals cannot match the discounts. It also argues that barriers to entry are high, and that specialty distributors, manufacturers and retailers do not meaningfully constrain the two. Whatever the outcome, the general lesson is clear: a buyer’s leverage comes from having an alternative, and it shrinks when the alternative disappears.
What the companies say
Covetrus responded the same day. It called the FTC’s case a “narrow and outdated view of the market” and said the lawsuit “does not reflect an accurate understanding of how veterinarians actually buy the products they need.” It said it is prepared to defend the deal in court.
Additionally, Covetrus argues that manufacturers sell directly to clinics. Clinics can also order from more than 40 distributors and thousands of manufacturers through online marketplaces. Cencora had not commented at the time of the reports. These are the company’s claims, and the court will test them against the FTC’s evidence.
Why market definition decides the case
Ultimately, market definition often decides whether merger cases win or lose. If the court accepts the FTC’s framing, a distinct market for distribution to clinics served by a small number of large players, the FTC argues the deal is presumptively unlawful under case law and the 2023 merger guidelines. If the court draws the market more widely, to include direct sales, online suppliers and retailers, the same deal looks less concentrated and may survive.
In other words, the two sides are not mainly arguing about arithmetic. They are arguing about where to draw the boundary before the arithmetic starts. Financial analysts quoted in reports did not expect the challenge to damage Cencora’s outlook, and they suggested it could look for alternative buyers if the sale is blocked. Therefore, that is commentary, not a prediction of the result.

Why the vet supply merger is being challenged now
The backdrop is cost. Reports widely show that US veterinary prices have risen faster than general inflation in recent years. Meanwhile, investor-backed groups have bought a growing share of clinics. These are broad trends, not findings about this merger. Even so, they help explain why a distribution deal that might once have passed quietly is now in federal court with thirteen states attached.
The question underneath
For anyone in the pet industry, anywhere, the principle matters more than the two companies. Companies usually defend supply chain consolidation on efficiency: larger buyers negotiate better, logistics improve, and distributors pass savings on. Sometimes that is true.
The FTC’s case is that here it would not be, and that savings would stay in the middle of the chain while clinics and then pet owners absorb the difference. Consequently, the court will now test that claim with evidence. Whichever way it goes, it will be one of the clearest answers yet to a question the industry has mostly debated in press releases: when the middle of a supply chain narrows, who keeps the money?
Pets News Network is India’s first dedicated media platform for the pet and animal industry. For breaking global pet news, brand coverage, and advertising enquiries, contact: info@petsnewsnetwork.com
